{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:54:17Z","timestamp":1789728857487,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00004\/03"],"award-info":[{"award-number":["MC_UU_00004\/03"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00004\/09"],"award-info":[{"award-number":["MC_UU_00004\/09"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00004\/07"],"award-info":[{"award-number":["MC_UU_00004\/07"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In a non-inferiority trial, the choice of margin depends on the expected control event risk. If the true risk differs from expected, power and interpretability of results can be affected. A non-inferiority frontier pre-specifies an appropriate non-inferiority margin for each value of control event risk. D3 is a non-inferiority trial comparing two treatment regimens in children living with HIV, designed assuming a control event risk of 12%, a non-inferiority margin of 10%, 80% power and a significance level (\u03b1) of 0.025. We consider approaches to choosing and implementing a frontier for this already funded trial, where changing the sample size substantially would be difficult.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In D3, we fix the non-inferiority margin at 10%, 8% and 5% for control event risks of \u22659%, 5% and 1%, respectively. We propose four frontiers which fit these fixed points, including a Smooth Away From Expected (SAFE) frontier. Analysis approaches considered are as follows: using the pre-specified significance level (\n                      <jats:italic>\u03b1<\/jats:italic>\n                      =0.025); always using a reduced significance level (to achieve\n                      <jats:italic>\u03b1<\/jats:italic>\n                      \u22640.025 across control event risks); reducing significance levels only when the control event risk differs significantly from expected (control event risk &lt;9%); and using a likelihood ratio test. We compare power and type 1 error for SAFE with other frontiers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Changing the significance level only when the control event risk is &lt;9% achieves approximately nominal (&lt;3%) type I error rate and maintains reasonable power for control event risks between 1 and 15%. The likelihood ratio test method performs similarly, but the results are more complex to present. Other analysis methods lead to either inflated type 1 error or badly reduced power. The SAFE frontier gives more interpretable results with low control event risks than other frontiers (i.e. it uses more reasonable non-inferiority margins). Other frontiers do not achieve power close (i.e. within 1%) to SAFE across the range of likely control event risks while controlling type I error.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The SAFE non-inferiority frontier will be used in D3, and the non-inferiority margin and significance level will be modified if the control event risk is lower than expected. This ensures results will remain interpretable if design assumptions are incorrect, while achieving similar power. A similar approach could be considered for other non-inferiority trials where the control event risk is uncertain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07586-5","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:02:14Z","timestamp":1692961334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Smooth Away From Expected (SAFE) non-inferiority frontier: theory and implementation with an application to the D3 trial"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4446-0730","authenticated-orcid":false,"given":"Matteo","family":"Quartagno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Turkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6718-7661","authenticated-orcid":false,"given":"Ian R.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"key":"7586_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/CVM-1-1-019","volume":"1","author":"SM Snapinn","year":"2000","unstructured":"Snapinn SM. Noninferiority trials. Curr Control Trials Cardiovasc Med. 2000;1:19\u201321.","journal-title":"Curr Control Trials Cardiovasc Med"},{"key":"7586_CR2","doi-asserted-by":"publisher","first-page":"e012594","DOI":"10.1136\/bmjopen-2016-012594","volume":"6","author":"S Rehal","year":"2016","unstructured":"Rehal S, Morris TP, Fielding K, et al. Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. BMJ Open. 2016;6:e012594.","journal-title":"BMJ Open"},{"key":"7586_CR3","doi-asserted-by":"publisher","unstructured":"Li Z, Quartagno M, B\u00f6hringer S, et al. Choosing and changing the analysis scale in non-inferiority trials with a binary outcome. Clin Trials. Epub ahead of print 2021. https:\/\/doi.org\/10.1177\/17407745211053790.","DOI":"10.1177\/17407745211053790"},{"key":"7586_CR4","doi-asserted-by":"publisher","unstructured":"Schumi J, Wittes JT. Through the looking glass. Trials. 12. Epub ahead of print 2011. https:\/\/doi.org\/10.1080\/00220612.1965.10778657.","DOI":"10.1080\/00220612.1965.10778657"},{"key":"7586_CR5","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1056\/NEJMra1510063","volume":"377","author":"L Mauri","year":"2017","unstructured":"Mauri L, D\u2019Agostino RB. Challenges in the design and interpretation of noninferiority trials. N Engl J Med. 2017;377:1357\u201367.","journal-title":"N Engl J Med"},{"key":"7586_CR6","unstructured":"Food and Drug Administration. Non-inferiority clinical trials to establish effectiveness - guidance for industry. 2016."},{"key":"7586_CR7","unstructured":"EMA. Guideline on the choice of the non-inferiority margin draft. Eur Med. 2005:2004\u20135."},{"key":"7586_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-020-4070-4","volume":"21","author":"M Quartagno","year":"2020","unstructured":"Quartagno M, Walker AS, Babiker AG, et al. Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation. Trials. 2020;21:1\u201312.","journal-title":"Trials"},{"key":"7586_CR9","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1177\/0962280216665418","volume":"27","author":"JS Koopmeiners","year":"2018","unstructured":"Koopmeiners JS, Hobbs BP. Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials. Stat Methods Med Res. 2018;27:1547\u201358.","journal-title":"Stat Methods Med Res"},{"key":"7586_CR10","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/sim.3871","volume":"29","author":"L Nie","year":"2010","unstructured":"Nie L, Soon G. A covariate-adjustment regression model approach to noninferiority margin definition. Stat Med. 2010;29:1107\u201313.","journal-title":"Stat Med"},{"key":"7586_CR11","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1177\/0962280218801134","volume":"28","author":"B Hanscom","year":"2019","unstructured":"Hanscom B, Hughes JP, Williamson BD, et al. Adaptive non-inferiority margins under observable non-constancy. Stat Methods Med Res. 2019;28:3318\u201332.","journal-title":"Stat Methods Med Res"},{"key":"7586_CR12","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240031593%0A."},{"key":"7586_CR13","doi-asserted-by":"publisher","first-page":"e421","DOI":"10.1016\/S2352-3018(16)30054-6","volume":"3","author":"Group B (PENTA16) T","year":"2016","unstructured":"Group B (PENTA16) T. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2\/3 trial. Lancet HIV. 2016;3:e421\u201330.","journal-title":"Lancet HIV"},{"key":"7586_CR14","doi-asserted-by":"publisher","first-page":"e0196239","DOI":"10.1371\/journal.pone.0196239","volume":"13","author":"A Turkova","year":"2018","unstructured":"Turkova A, Moore CL, Butler K, et al. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): extended follow-up results of a randomised, open-label, non-inferiority trial. PLoS One. 2018;13:e0196239.","journal-title":"PLoS One"},{"key":"7586_CR15","unstructured":"Food and Drug Administration. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment guidance for industry. 2015."},{"key":"7586_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1137\/1037125","volume":"37","author":"TJ Ypma","year":"1995","unstructured":"Ypma TJ. Historical development of the Newton-Raphson method. SIAM Rev. 1995;37:531\u201351.","journal-title":"SIAM Rev"},{"issue":"11","key":"7586_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/sim.8086","volume":"38","author":"TP Morris","year":"2019","unstructured":"Morris TP, White IR, Crowther MJ. Using simulation studies to evaluate statistical methods. Stat Med. 2019;38(11):1\u201329.","journal-title":"Stat Med"},{"key":"7586_CR18","unstructured":"Quartagno M. dani: design and analysis of non-inferiority trials. 2022. https:\/\/cran.r-project.org\/package=dani."},{"key":"7586_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17:873\u201390.","journal-title":"Stat Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07586-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07586-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07586-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:35:35Z","timestamp":1700584535000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07586-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7586"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07586-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2175825\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"17 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"556"}}